$INSP

Are New Sleep Apnea Billing Codes Altering The Investment Case For Inspire Medical Systems (INSP)?

Inspire Medical Systems (INSP) announced that the AMA CPT Editorial Panel approved new Category I CPT codes for its Inspire V sleep apnea system, effective January 1, 2028. These codes may improve long-term reimbursement clarity and provider workflows. Analysts expect revenue of $991.6M and earnings of $74.2M by 2029, with some optimistic views projecting higher figures. The company's near-term performance depends on center training, contracting, and coding education.

Original reporting
Published Oct 4, 2026, 1:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 4, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$INSP
Neutral
medium confidence
Mentioned
$INSP
Relevance
6/10
AlphAI data visualization · based on simplywall.st
Decision brief

The 30-second read

$INSPNeutralLow
01

Why it matters

The new CPT codes could reduce uncertainty, supporting longer‑term revenue visibility, but near‑term execution still hinges on training and provider adoption.

02

Market read

Regulatory coding improvement for INSP may gradually improve its valuation, but the effect is long‑dated and modest.

03

What to watch

Potential delays in CMS valuation and provider adoption could mute the expected upside.

Relevance 6/10Novelty 6/10Timing: long‑term outlook, codes effective 2028

Background

Inspire Medical Systems (INSP) is a leading provider of implantable sleep‑apnea therapy devices. Reimbursement coding has been a key uncertainty for its growth.

Company-level read

Ticker impact

$INSPNeutralMedium confidence
Context

AMA CPT Editorial Panel approved new Category I CPT codes for Inspire V, effective Jan 1, 2028, improving reimbursement clarity.

Expected impact

potential modest upside as investors price in clearer reimbursement outlook

Evidence & confidence

The coding change is a regulatory improvement but does not immediately affect cash flow; impact will materialize over years.

Market effects

May improve perception of medtech reimbursement environment, benefiting other sleep‑apnea device makers.

U.S. healthcare reimbursement landscape sees incremental clarity; limited immediate regional effect.

Low global impact; primarily U.S. regulatory relevance.

Counterpoint

Investors may view the delayed effective date and ongoing execution risks as outweighing the coding benefit.

Key entities

  • AMA CPT Editorial Panel

    Approved the new Category I CPT codes for Inspire V.

  • CMS

    Will set valuation for the new codes, influencing reimbursement rates.

Related articles

$INSPMed

Inspire Medical (INSP): How Much Optimism Is Baked Into This Medtech Stock?

Inspire Medical Systems (INSP) reported a 7.6% revenue decline to $200.6M in Q2, with US sales driving the drop. Despite this, the company boasts an 85.5% gross margin, $415.2M in cash, and raised 2026 revenue guidance to $835M-$875M. The AMA approved new billing codes for its Inspire V system, a key reimbursement milestone. However, the stock trades at a high forward P/E of 59.17, reflecting investor optimism about future earnings.

$INSPMedAI 8/10

Inspire Secures AMA Approval For New Hypoglossal Nerve Stimulation Codes

Inspire Medical Systems (INSP) received AMA approval for new CPT codes covering hypoglossal nerve stimulation procedures, including its Inspire V system. The codes, effective January 1, 2028, aim to simplify reimbursement and expand patient access. CMS will determine reimbursement values, with proposed valuations expected in July 2027. INSP stock closed at $70.78, up 2.05%.

$INSPMedAI 8/10

Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel

Inspire Medical Systems (INSP) announced the AMA approved new CPT codes for its Inspire V system, effective January 1, 2028. The company expects this to streamline reimbursement and expand patient access. CMS will determine Medicare payments for the new codes, with proposed valuations expected in July 2027 and final valuations in November 2027.

$INSPHigh

Why Inspire Medical Systems (INSP) Stock Is Up Today

Inspire Medical Systems (INSP) stock rose 7.4% after Stifel raised its price target to $80.00, citing positive sentiment. Shares later cooled to $70.71, up 3.8%. The company's shares are volatile, with significant moves tied to regulatory changes and analyst upgrades. INSP is down 23.4% YTD and 50.9% off its 52-week high.

$INSPMed

Is Inspire Medical Systems (INSP) Undervalued After Its Earnings Beat And Higher 2026 Guidance?

Inspire Medical Systems (INSP) reported Q2 2026 adjusted EPS of $0.14, beating estimates, and raised its 2026 revenue and earnings guidance. Despite U.S. coding and reimbursement challenges, international revenues supported the revised outlook. The stock has seen volatility, with a 50.86% 90-day return but a 32.65% YTD decline. Analysts' price targets range from $40 to $85, with a consensus of $60.40, suggesting a 3% overvaluation.